Back
Ventas, Inc. 10K Form
Buy
70
VTR
Ventas, Inc.
Last Price:
$85.25
Seasonality Move:
3%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2024-02-15 | 10K | VTR/Ventas, Inc. Annual |
| 2023-11-03 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-08-04 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-05-09 | 10Q | VTR/Ventas, Inc. Quarterly |
| 2023-02-10 | 10K | VTR/Ventas, Inc. Annual |
Receive VTR News And Ratings
See the #1 stock for the next 7 days that we like better than VTR
VTR Financial Statistics
Sales & Book Value
| Annual Sales: | $5.8B |
|---|---|
| Cash Flow: | $367.7M |
| Price / Cash Flow: | 29.94 |
| Annual Sales: | $26.38 |
| Price / Book: | 3.23 |
Profitability
| EPS (TTM): | 0.54220 |
|---|---|
| Net Income (TTM): | $261.5M |
| Gross Margin: | $1.1B |
| Return on Equity: | 2.16% |
| Return on Assets: | 0.98% |
Ventas, Inc. Earnings Forecast
Key Ventas, Inc. Financial Ratios
-
The Gross Profit Margin over the past 39 years for VTR is 18.87%.
-
The Selling, General & Administrative Expenses for VTR have been equal to 0.00% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 222.72% of Operating Income.
-
The Net Earning history of VTR is 4.48% of Total Revenues.
-
Per Share Earnings over the last 39 years have been positive in 23 years.
Ventas, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | S&P500 |
|---|---|
| Industry: | Health Care REITs |
| Sector: | Real Estate |
| Current Symbol: | VTR |
| CUSIP: | 92276F |
| Website: | ventasreit.com |
Debt
| Debt-to-Equity Ratio: | 1.06 |
|---|---|
| Current Ratio: | 0.51 |
| Quick Ratio: | 0.34 |
Price-to-Earnings
| Trailing P/E Ratio: | 156.86 |
|---|---|
| Forward P/E Ratio: | 90.36 |
VTR Technical Analysis vs Fundamental Analysis
Buy
70
Ventas, Inc. (VTR)
is a Buy
Is Ventas, Inc. a Buy or a Sell?
-
Ventas, Inc. stock is rated a BuyThe current Ventas, Inc. [VTR] share price is $85.24. The Score for VTR is 70, which is 40% above its historic median score of 50, and infers lower risk than normal.